CVR Capital RaiseCapital Raise VANCOUVER, BC / November 8, 2021 / CVR Medical Corp. (CVM.V) (TSXV: CVM) (OTCQB: CRRVF) ("CVR Medical" or the "Company" or "we") a Canadian listed and US based healthcare company in the medical device market is pleased to announce a non-brokered private placement (the “Offering”) and debt settlement subject to regulatory approval by the TSX Venture Exchange. The Offering will consist of approximately 7,500,000 units at a market price CDN$0.020 per unit for gross proceeds of up to US$150,000, subject to approval by the TSX Venture Exchange (the “Exchange”) upon acceptance of the Company’s application for a discretionary waiver of the $0.05 minimum pricing requirement. Pursuant to the Offering, each unit will consist of one common share of the Company and one transferable common share purchase warrant exercisable to acquire an additional common share of the Company for a term of five years from issuance at a price of $0.12 per share. The proceeds from the Offering will be used for Annual General Meeting costs and related filings fees and expenses to maintain the Company’s filings and reporting obligations. In addition, and subject to Exchange approval, the Company is also proposing to settle US$200,000 in outstanding debt with the issuance of common shares, also at the Offering price of CDN$0.020 per share. The debt due relates to amounts advanced to the Company by current and former directors and officers for payment of Company expenses. These actions are necessary first steps in relaunching operations under new leadership, with the ultimate goal of commercializing the Carotid Stenotic Scan device. The common shares and warrants will be subject to a four month hold period under applicable securities laws in Canada and the rules of the Exchange. The Offering may be closed in one or more tranches, the first tranche is expected to close on immediately following conditional approval of the Exchange, subject to customary closing conditions, including the approval of the Exchange. About CVR Medical CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its disruptive, proprietary Carotid Stenotic Scan device ("CSS"). The CSS is a diagnostic tool that encompasses subsonic, infrasonic, and low frequency sound wave analysis technology. The CSS is a patented device designed to detect and measure carotid arterial stenosis. CVR Medical's shares are listed on the OTCQX under the symbol "CRRVF". The Company is listed for trading under the symbol “CVM”. Additional information regarding the Company can be found in our recent filings with the SEDAR as well as the information maintained on our website at www.cvrmed.com ON BEHALF OF THE BOARD: (signed) Paul Blunden, M.D. President & Director, interim CEO and C